For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
0
views
101
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      309
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this review, we summarize and discuss the potential mechanisms of stroke protection by GLP-1RAs. GLP-1RAs exert multiple anti-atherosclerotic effects contributing to stroke prevention such as enhanced plaque stability, reduced vascular smooth muscle proliferation, increased nitric oxide, and improved endothelial function. GLP-1RAs also lower the risk of stroke by reducing traditional stroke risk factors including hyperglycemia, hypertension, and dyslipidemia. Independently of these peripheral actions, GLP-1RAs show direct cerebral effects in animal stroke models, such as reduction of infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, blood–brain barrier permeability, and increased neurogenesis, neuroplasticity, angiogenesis, and brain perfusion. Despite these encouraging findings, further research is still needed to understand more thoroughly the mechanisms by which GLP-1RAs may mediate stroke protection specifically in the human diabetic brain.

          Related collections

          Most cited references101

          • Record: found
          • Abstract: found
          • Article: not found

          Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

          Dena Ettehad, Connor Emdin, Amit Kiran … (2016)
          The benefits of blood pressure lowering treatment for prevention of cardiovascular disease are well established. However, the extent to which these effects differ by baseline blood pressure, presence of comorbidities, or drug class is less clear. We therefore performed a systematic review and meta-analysis to clarify these differences.
          Article 0 comments Cited 714 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke

            Changjun Yang, Kimberly Hawkins, Sylvain Doré … (2019)
            As part of the neurovascular unit, the blood-brain barrier (BBB) is a unique, dynamic regulatory boundary that limits and regulates the exchange of molecules, ions, and cells between the blood and the central nervous system. Disruption of the BBB plays an important role in the development of neurological dysfunction in ischemic stroke. Blood-borne substances and cells have restricted access to the brain due to the presence of tight junctions between the endothelial cells of the BBB. Following stroke, there is loss of BBB tight junction integrity, leading to increased paracellular permeability, which results in vasogenic edema, hemorrhagic transformation, and increased mortality. Thus, understanding principal mediators and molecular mechanisms involved in BBB disruption is critical for the development of novel therapeutics to treat ischemic stroke. This review discusses the current knowledge of how neuroinflammation contributes to BBB damage in ischemic stroke. Specifically, we provide an updated overview of the role of cytokines, chemokines, oxidative and nitrosative stress, adhesion molecules, matrix metalloproteinases, and vascular endothelial growth factor as well as the role of different cell types in the regulation of BBB permeability in ischemic stroke.
            Article 0 comments Cited 234 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

              Naveed Sattar, Matthew M Y Lee, Søren L. Kristensen … (2021)
              GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes.
              Article 0 comments Cited 229 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Bruno Vergès: bruno.verges@chu-dijon.fr
                Journal
                Journal ID (nlm-ta): Cardiovasc Diabetol
                Journal ID (iso-abbrev): Cardiovasc Diabetol
                Title: Cardiovascular Diabetology
                Publisher: BioMed Central (London )
                ISSN (Electronic): 1475-2840
                Publication date (Electronic): 15 November 2022
                Publication date PMC-release: 15 November 2022
                Publication date Collection: 2022
                Volume: 21
                Electronic Location Identifier: 242
                Affiliations
                [1 ]GRID grid.5613.1, ISNI 0000 0001 2298 9313, Department of Endocrinology, Diabetes and Metabolic Disorders, Dijon University Hospital, INSERM Unit, LNC-UMR 1231, , University of Burgundy, ; Dijon, France
                [2 ]Department of Cardiology, EpiMaCT - INSERM UMR, Dupuytren University Hospital, Limoges University, 1094 & IRD 270, Limoges, France
                [3 ]EA4245 Transplantation, Immunity & Inflammation, Department of Cardiology, University of Tours, Tours University Hospital, Tours, France
                [4 ]Paris Cardiovascular Research CenterUMR-970Department of Pharmacology, INSERM, Georges-Pompidou European Hospital, Paris City University, Paris, France
                [5 ]GRID grid.462318.a, University of Nantes, Nantes University Hospital Centre, CNRS, INSERM, L’institut du Thorax, ; Nantes, France
                [6 ]GRID grid.414093.b, ISNI 0000 0001 2183 5849, Department of Nuclear Medicine, DMU IMAGINA, , Georges-Pompidou European Hospital, APHP, Paris City University, ; Paris, France
                [7 ]GRID grid.412041.2, ISNI 0000 0001 2106 639X, Department of Endocrinology, Diabetes, and Nutrition, , University of Bordeaux, INSERM U1034, ; Pessac, France
                [8 ]Neurology and Stroke Center, SOS-TIA Clinic, Bichat Hospital, University of Paris, Paris, France
                Article
                Publisher ID: 1686
                DOI: 10.1186/s12933-022-01686-3
                PMC ID: 9667639
                PubMed ID: 36380358
                SO-VID: a3ebf783-4929-4222-8ce6-9e45c54483f9
                Copyright © © The Author(s) 2022
                License:

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                Date received : 5 September 2022
                Date accepted : 18 October 2022
                Categories
                Subject: Review
                Custom metadata
                issue-copyright-statement © The Author(s) 2022

                ScienceOpen disciplines: Endocrinology & Diabetes
                Keywords: stroke,glucagon-like peptide-1 receptor agonists,glp-1,neuroprotection,mechanisms
                Data availability:
                ScienceOpen disciplines: Endocrinology & Diabetes
                Keywords: stroke, glucagon-like peptide-1 receptor agonists, glp-1, neuroprotection, mechanisms

                Comments

                Comment on this article